Market Overview

GlycoMimetics to Present at Four Investor Conferences This Month


GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that it will present
at four investor conferences during the month of March, including:

30th Annual ROTH Conference
11 – 14, 2018, The Ritz Carlton, Dana Point, CA

CFO Brian Hahn
will present on March 12 at 3:30 p.m. PT.

Cowen 38th Annual Health Care Conference
11 – 14, 2018, Copley Place Marriott, Boston, MA

CEO Rachel
King will present on March 14 at 9:20 a.m. ET.

BioCentury: 25th Annual Future Leaders in
the BioTech Industry

March 23, 2018, Millennium Broadway
Hotel & Conference Center, New York, NY

Mrs. King will
present in room 311 at 2:30 p.m. ET.

Needham & Company's 17th Annual
HealthCare Conference

March 27 – 28, 2018, Westin Grand
Central Hotel, New York, NY

Mrs. King will present on March 27
at 8:00 a.m. ET.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics' most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate,
GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is currently being
evaluated in a Phase 1 clinical trial for the treatment of multiple
myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation
for the treatment of adult AML patients with relapsed/refractory
disease. GlycoMimetics has also recently initiated a Phase 1 clinical
trial with a third drug candidate, GMI-1359, a combined CXCR4 and
E-selectin antagonist. GlycoMimetics is located in Rockville, MD in
the BioHealth Capital Region. Learn more at

View Comments and Join the Discussion!